Geode Capital Management LLC Acquires 23,413 Shares of Century Therapeutics, Inc. (NASDAQ:IPSC)

Geode Capital Management LLC grew its holdings in Century Therapeutics, Inc. (NASDAQ:IPSC) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 991,595 shares of the company’s stock after purchasing an additional 23,413 shares during the period. Geode Capital Management LLC owned about 1.17% of Century Therapeutics worth $1,002,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Sei Investments Co. acquired a new stake in Century Therapeutics in the 4th quarter valued at $53,000. Barclays PLC grew its holdings in shares of Century Therapeutics by 283.6% in the 3rd quarter. Barclays PLC now owns 61,945 shares of the company’s stock valued at $106,000 after acquiring an additional 45,797 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Century Therapeutics by 257.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company’s stock valued at $123,000 after acquiring an additional 51,664 shares in the last quarter. Finally, State Street Corp increased its position in shares of Century Therapeutics by 7.4% in the third quarter. State Street Corp now owns 836,914 shares of the company’s stock valued at $1,431,000 after acquiring an additional 57,323 shares during the last quarter. Institutional investors own 50.20% of the company’s stock.

Analyst Ratings Changes

IPSC has been the subject of several recent research reports. Chardan Capital reduced their price target on Century Therapeutics from $11.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, March 24th. Piper Sandler cut their price objective on Century Therapeutics from $4.00 to $2.00 and set an “overweight” rating for the company in a report on Thursday, March 20th. HC Wainwright lowered their target price on shares of Century Therapeutics from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, April 3rd. Finally, Guggenheim reiterated a “buy” rating on shares of Century Therapeutics in a research note on Friday, March 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $4.40.

Century Therapeutics Price Performance

IPSC stock opened at $0.56 on Friday. Century Therapeutics, Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $3.70. The stock has a market capitalization of $47.85 million, a price-to-earnings ratio of -0.30 and a beta of 1.83. The business’s fifty day moving average price is $0.54 and its two-hundred day moving average price is $0.94.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.02. The business had revenue of $4.18 million for the quarter, compared to the consensus estimate of $0.67 million. Century Therapeutics had a negative return on equity of 61.66% and a negative net margin of 4,837.73%. Research analysts expect that Century Therapeutics, Inc. will post -1.61 EPS for the current year.

Century Therapeutics Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.